A Phase 2 Study of the Effect of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib on Disease Response in Patients With High Risk Smoldering Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 26 Mar 2018
At a glance
- Drugs Ibrutinib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 22 Mar 2018 Planned End Date changed from 1 Nov 2018 to 1 Dec 2023.
- 22 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2023.
- 10 Jun 2017 Biomarkers information updated